NASDAQ$HALO
Halozyme Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Halozyme's financial performance increased, driven by revenue growth and strategic acquisitions.
Halozyme reported a 38% year-over-year increase in revenue to $162.1 million for Q1 2023, driven by royalty revenue and product sales from the Antares Pharma acquisition. GAAP diluted earnings per share was $0.29, and non-GAAP diluted earnings per share was $0.47. The company reiterates its 2023 revenue guidance of $815-$845 million and EBITDA of $415-$440 million.
- Revenue increased 38% year-over-year to $162.1 million.
- Royalty revenue increased 43% year-over-year to $99.6 million.
- GAAP diluted earnings per share was $0.29, while non-GAAP diluted earnings per share was $0.47.
- Halozyme repurchased 4.2 million shares of common stock for $150.0 million in Q1 2023.
Headline financials
Revenue & EPS history
Halozyme · Revenue · Quarterly
$162M
Revenue by segment
Halozyme · $101M total across 2 segments · Q1 2023
- Royalties$99.6M+43.2%98.3%
- Revenues under collaborative agreements$1.71M-93.3%1.7%
Forward guidance
Halozyme is reiterating its financial guidance for 2023, expecting total revenue of $815 million to $845 million, royalty revenue of $445 million to $455 million, EBITDA of $415 million to $440 million, and non-GAAP diluted earnings per share of $2.50 to $2.65.
Tailwinds
- Total revenue of $815 million to $845 million, representing growth of 23% to 28% over 2022.
- Revenue from royalties of $445 million to $455 million, representing growth of 23% to 26%.
- EBITDA of $415 million to $440 million, representing growth of >30% over 2022.
- Non-GAAP diluted earnings per share of $2.50 to $2.65, representing growth of >10% over 2022.
- Growth is primarily driven by continued strength in Wave 2 products and full year auto-injector royalty and product contribution.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+1.8%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+1.8%
Avg return
30 days after
62%
32 / 52 earnings
Positive
+18.2%
Q1 2025
Best reaction
-12.8%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.7% | +1.1% | +6.5% | |
| Q4 2025 | -9.0% | -12.2% | -21.2% | |
| Q3 2025 | +2.7% | +3.1% | -4.9% | |
| Q1 2025 | +18.2% | +12.1% | -8.6% | |
| Q3 2024 | +13.0% | +16.1% | -4.7% | |
| Q2 2024 | +3.9% | +5.9% | +17.2% | |
| Q1 2024 | +2.8% | +5.6% | +25.9% | |
| Q4 2023 | +6.3% | +12.4% | +11.4% | |
| Q3 2023 | +9.1% | +4.7% | +12.3% | |
| Q2 2023 | +1.5% | +4.1% | -6.8% | |
| Q1 2023 | +13.9% | +8.9% | +12.8% | |
| Q4 2022 | +0.1% | -1.0% | -32.7% | |
| Q3 2022 | +7.4% | +16.6% | +25.0% | |
| Q2 2022 | -2.1% | -4.2% | -11.9% | |
| Q1 2022 | +3.3% | +8.2% | +20.4% | |
| Q4 2021 | +3.1% | +8.6% | +18.3% | |
| Q3 2021 | +2.6% | +4.3% | -15.0% | |
| Q2 2021 | +1.8% | +2.4% | +3.8% | |
| Q1 2021 | -10.3% | -9.5% | -17.2% | |
| Q4 2020 | +5.7% | -7.1% | -15.2% | |
| Q3 2020 | +12.9% | +34.6% | +45.2% | |
| Q2 2020 | -2.7% | -3.7% | -3.2% | |
| Q1 2020 | +0.2% | +2.7% | -1.4% | |
| Q4 2019 | -4.7% | -10.4% | -22.4% | |
| Q3 2019 | +6.4% | +13.9% | +12.8% | |
| Q2 2019 | -0.9% | -5.1% | -5.3% | |
| Q1 2019 | -3.1% | -5.9% | -10.9% | |
| Q4 2018 | -0.4% | +1.8% | -8.2% | |
| Q3 2018 | +0.7% | +0.6% | -1.6% | |
| Q2 2018 | +0.3% | -2.6% | +2.5% | |
| Q1 2018 | -7.3% | -3.0% | -7.2% | |
| Q4 2017 | +3.8% | +7.2% | +9.9% | |
| Q3 2017 | +12.2% | +6.9% | +11.5% | |
| Q2 2017 | -4.0% | -9.7% | -0.7% | |
| Q1 2017 | -1.6% | +3.1% | -7.3% | |
| Q4 2016 | +0.2% | +5.6% | +1.2% | |
| Q3 2016 | +14.2% | +48.7% | +33.7% | |
| Q2 2016 | -0.4% | +1.6% | +6.2% | |
| Q1 2016 | +3.7% | — | — | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | -12.8% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +2.8% | — | — | |
| Q4 2014 | +1.1% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +1.7% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q3 2011 | -1.4% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | +5.2% | — | — | |
| Q1 2010 | -2.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro